Literature DB >> 32496961

Podoplanin expression in cutaneous squamous cell carcinomas and its relationship to histopathological prognostic factors.

Duygu Gülseren1, Özay Gököz2, Sevilay Karahan3, Ayşen Karaduman1.   

Abstract

There are several clinicopathological factors associated with the prognosis of cutaneous squamous cell carcinomas (cSCC), but there remains a lack of molecular markers associated with cSCC tumor progression. This study aimed to determine the association between histopathological prognostic parameters and tumoral podoplanin expression in cSCC. This study included 63 paraffin embedded cSCC samples that were evaluated for tumoral podoplanin expression using immunohistochemistry. Among the 63 tumor samples, 27% lacked podoplanin expression, 22% exhibited diffuse podoplanin expression, and 51% exhibited focal podoplanin expression. Tumoral podoplanin expression was correlated with lymphovascular invasion and lymph node metastasis (p value < 0.05, for both). Additional research is needed to further delineate how the tumoral podoplanin expression can be used as a prognostic marker in patients with cSCC.

Entities:  

Keywords:  D2-40; Squamous cell carcinoma; immunohistochemistry; monoclonal antibody; pathology; podoplanin; prognosis; skin

Year:  2020        PMID: 32496961     DOI: 10.1080/01478885.2020.1757872

Source DB:  PubMed          Journal:  J Histotechnol        ISSN: 0147-8885            Impact factor:   0.714


  2 in total

Review 1.  The Role of Podoplanin in Skin Diseases.

Authors:  Jun Asai
Journal:  Int J Mol Sci       Date:  2022-01-24       Impact factor: 5.923

Review 2.  Role of immunohistochemistry in the diagnosis and staging of cutaneous squamous-cell carcinomas (Review).

Authors:  Elena Bălășescu; Andreea-Cristina Gheorghe; Andreea Moroianu; Gabriela Turcu; Alice Brînzea; Mihaela Antohe; Anastasia Hodorogea; Lorena Manea; Mihaela Balaban; Răzvan Andrei; Ionela Hulea; Cristiana Gabriela Popp; Luciana Nichita; Mirela Daniela Cioplea; Sabina Andrada Zurac; Daniela Adriana Ion; Roxana Ioana Nedelcu
Journal:  Exp Ther Med       Date:  2022-04-11       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.